The NPN Application Process in Canada — A Step-by-Step Guide for Manufacturers

A supplement manufacturer preparing to launch a new product in Canada faces a regulatory pathway that is distinct from what they may have encountered in the United States or Europe. The product — a combination herbal formula — requires a Natural Product Number (NPN) before it can be sold. The application process is not simply a matter of submitting a label and a safety dossier. It requires a structured evidence package, a site licence, and a clear understanding of how Health Canada’s Natural Health Products Directorate (NHPD) evaluates claims.

This guide is for manufacturers, importers, and their regulatory affairs teams navigating the NPN application process for the first time or seeking to improve their submission quality. We walk through each stage of the process, highlight the evidence standards that determine approval timelines, and flag the most common reasons submissions are returned or delayed.

What Is an NPN and When Is It Required?

A Natural Product Number is a licence issued by Health Canada that authorizes the sale of a natural health product (NHP) in Canada. Under the Natural Health Products Regulations (SOR/2003-196), every NHP sold in Canada must carry an NPN (or a Homeopathic Medicine Number, DIN-HM, for homeopathic products) on its label. Products sold without a valid NPN are in violation of the Food and Drugs Act.

The NHP Regulations define natural health products broadly. The category includes vitamins and minerals, herbal remedies, homeopathic medicines, traditional medicines, probiotics, and certain amino acids and essential fatty acids. If your product falls within this definition, an NPN is required regardless of whether the product is manufactured domestically or imported.

The Two Licensing Requirements: Product Licence and Site Licence

Before submitting a product licence application, manufacturers and importers must hold — or ensure their Canadian partner holds — a Site Licence issued under the NHP Regulations. The site licence confirms that the facility meets the Good Manufacturing Practices requirements set out in Schedule 2 of the NHP Regulations. We cover site licensing in detail in a separate article; for now, the key point is that a product licence application will not be approved if the manufacturing or importing site does not have a valid site licence for the relevant activities.

The Product Licence Application (PLA) is the submission that results in an NPN being issued. It must demonstrate that the product is safe, effective, and of high quality for the intended use.

Step-by-Step: The NPN Application Process

Step 1: Classify Your Product

Before preparing your submission, confirm that your product is classified as an NHP rather than a food, drug, or cosmetic. Health Canada uses a product classification process, and the regulatory pathway — and evidence requirements — differ significantly depending on classification. If there is ambiguity, a pre-submission meeting or a classification request to Health Canada may be warranted.

Step 2: Determine the Application Category

Health Canada processes NPN applications through a tiered system based on the complexity of the evidence required:

• Category I: Products with well-established safety and efficacy supported by compendial monographs (e.g., Health Canada’s own NHP monographs, or recognized pharmacopoeial monographs). These applications typically receive faster review.
• Category II: Products where evidence comes from traditional use references (at least 50 years of use, with at least 15 years in a Western context, or evidence from a recognized traditional medicine system).
• Category III: Products requiring clinical trial evidence or other non-traditional evidence to support the proposed claims.

Selecting the correct category and matching your evidence package to that category is one of the most consequential decisions in the application process. Submitting a Category III application when a Category I pathway is available wastes time and resources; submitting a Category I application with insufficient monograph coverage will result in a deficiency notice.

Step 3: Prepare the Evidence Package

The core of the PLA is the evidence package supporting the product’s safety, efficacy, and quality. The specific requirements depend on the application category, but all applications must address:

Safety: Demonstrate that the product is safe for the intended population at the proposed dose and duration of use. For Category I applications, safety is typically established through the applicable monograph. For Category III applications, clinical or non-clinical safety data may be required.

Efficacy: Substantiate each health claim with appropriate evidence. Health Canada’s NHP monographs specify the acceptable claims, doses, and populations for many common ingredients. Claims that go beyond what a monograph supports require additional evidence.

Quality: Provide specifications for each medicinal ingredient, including identity, purity, and potency. Reference standards should be traceable to a recognized pharmacopoeia where available. For herbal ingredients, botanical identity and marker compound specifications are typically required.

Step 4: Prepare the Product Licence Application

The PLA is submitted through Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) online portal. The submission must include:

• Product information (name, dosage form, route of administration)
• Medicinal ingredients with quantities per dosage unit
• Non-medicinal ingredients
• Recommended conditions of use (dose, duration, population, cautions, contraindications)
• Evidence documents supporting each claim
• Label draft (must comply with NHP labelling requirements under Schedule 4 of the NHP Regulations)
• Manufacturing information (site licence number, manufacturer details)

Step 5: Respond to Deficiency Notices

Health Canada reviewers may issue one or more deficiency notices requesting clarification or additional information. Response timelines are specified in the notice, and failure to respond within the required timeframe may result in the application being closed. We recommend treating deficiency notices as a dialogue with the reviewer — responses should be precise, reference specific sections of the submission, and avoid introducing new claims or evidence not previously included.

Step 6: Receive the NPN and Maintain Compliance

Once approved, the NPN is issued and must appear on the product label. Post-market obligations include reporting serious adverse reactions, notifying Health Canada of significant changes to the product or its manufacturing, and maintaining records in accordance with the NHP Regulations. Requirements may vary depending on the nature of any post-approval changes.

Common Reasons NPN Applications Are Delayed or Rejected

• Insufficient evidence to support the proposed health claims
• Mismatch between the claimed population and the evidence base (e.g., adult evidence used to support a children’s product claim)
• Non-compliant label draft (missing required elements under Schedule 4)
• Manufacturing site does not hold a valid site licence for the relevant activities
• Botanical identity not adequately established for herbal ingredients
• Proposed dose outside the range supported by the applicable monograph

Practical Checklist: NPN Application Readiness

• Confirm product classification as an NHP (not a food, drug, or cosmetic)
• Identify the applicable application category (I, II, or III)
• Confirm the manufacturing/importing site holds a valid NHP site licence
• Map each health claim to a supporting monograph or evidence document
• Prepare ingredient specifications with pharmacopoeial references where available
• Draft the product label in compliance with Schedule 4 of the NHP Regulations
• Review the submission for completeness before filing — incomplete submissions generate avoidable deficiency notices
• Establish a post-market adverse reaction reporting procedure

The NPN application process is manageable with the right preparation, but the evidence and documentation standards are specific. Requirements may vary depending on the product type, the claims being made, and the applicable monographs. We recommend engaging a regulatory consultant familiar with Health Canada’s NHP framework before finalizing your submission strategy.

At Androxa, we support manufacturers and importers through the NPN application process, from product classification through submission and post-market compliance. Reach out at testing-lab.ca to discuss your product.